NVS still has EDP-239 and DEB025, although the latter may be on life support. The deal with Enanta was struck only six months ago (#msg-72334186), so I don’t think we can say that NVS has lost all interest in HCV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”